glp 1 drugs and autoimmune disease GLP-1 Obesity May Lower Risk of Heart for People With Disease Frontiers | The immunomodulatory effects

doi: 10.1155/2014/917981 33 CorkS

Drug Discov Today

Perhaps nowhere is this tension more apparent than in the case of chronic kidney disease (CKD)a condition that is currently difficult to treat, typically leading to dialysis, transplant, or even death

Similarly, observational studies using healthcare databases have suggested that patients prescribed GLP-1 agonists for diabetes or obesity appear to have lower rates of alcohol-related hospital admissions and reduced self-reported drinking compared to those on other medications, though these findings are limited by potential confounding factors

This article is part of EMARKETERs client-only subscription Briefingsdaily newsletters authored by industry analysts who are experts in marketing, advertising, media, and tech trends